Regulatory Watch Mechanism for Medical Devices in Morocco
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Regulatory change in the Moroccan medical device sector travels through two vehicles: the Official Gazette (Bulletin officiel), which publishes laws, decrees and ministerial orders, and the AMMPS service checklists, which reflect the actual practice of application requirements. The GRZAN watch mechanism uses these two as dual sources, starts a review whenever one of five trigger conditions is met, and treats checklist version numbers as the most sensitive signal — a checklist revision often affects ongoing projects earlier than an amendment to the law itself. The reasoning is structural: where so much of the detailed rulebook lives in administrative texts, the operative law is effectively a moving target, and a monitoring system that reads only statutes will systematically miss the changes that matter first. Post-market compliance — vigilance, recalls, inspections — inherits exactly the same dynamics, since the obligations it monitors are themselves defined in those companion texts. A change to a checklist or a companion decree can therefore alter what must be reported, to whom, in which format, without a single word of the statute changing.
2. Legal basis
| Legal instrument | Reference / number | Publication date | Provisions |
|---|---|---|---|
| Medical Devices Law (Loi n° 84-12) | Dahir n° 1-13-90 | August 30, 2013 (BO n° 6188, September 19, 2013) | Article 50 (one-year deadline for publication of implementing regulations in the Official Gazette); Articles 18, 19 and 23 (delegated-legislation clauses) |
| Implementing decree for Law 84-12 (Décret n° 2-14-607) | Décret n° 2-14-607 | September 18, 2014 | Articles 4 and 6 |
| AMMPS registration checklist / establishment declaration checklist | DE ER DM/01 (9th edition, 2025-01-30) / DE RD-IS-PS/04 (2026-05-11) | See respective application dates | Item-by-item requirements |
3. Expert insights
Insight 1: the delegated-legislation clauses make continuous tracking necessary. Law 84-12 contains at least five clauses that hand concrete requirements to later regulatory texts: Article 18 (list of second-hand devices), Article 19 (radiation protection), Article 23 (traceability rules), Article 10 (mandatory maintenance list) and Article 11 (good practice). The statutory wording of these provisions will not change, but the companion texts will — tracking only the statutes means missing every change that actually affects operations. The five clauses also share a common feature: each leaves a list, a rule or a technical standard to be fixed later, which is exactly the category of text that is easiest to revise quietly.
Insight 2: checklist version numbers are the most sensitive early signal. The 9th edition of the registration checklist applies from January 30, 2025, and the establishment declaration checklist from May 11, 2026 — about 15 months apart. A checklist revision means the acceptance criteria have moved, and any dossier in preparation must be frozen and re-reviewed immediately against the new edition. The same signal value applies to post-market files: a revision to any service checklist can change what the authority expects to see during an inspection or a reporting exchange, not only at submission.
Insight 3: Article 50 itself embodies the mechanism that companion texts determine entry into force. The law applies from the date of entry into force of its implementing regulations, and those regulations must be published in the Official Gazette within 1 year of the law. This establishes the Official Gazette as the authoritative marker of when obligations begin. For a monitoring system, the lesson is procedural: publication in the Gazette, not ministerial announcements or informal practice, is the event that starts or changes duties, so the Gazette line of the watch must never be subordinated to the checklist line.
Insight 4: the institutional transition period is a high-variation window. As the AMMPS takes over the functions of the DMP, the authority’s name, checklist numbering system and submission channels are all in flux. The launch of the Tarkhiss platform in March 2026 (currently covering cosmetics) coexisting with device dossiers still going through offline software is typical of this period (a practical estimate). During such a transition, submission requirements and receipt formats can change between two filings of the same dossier type, which makes version and date recording on every submission receipt essential.
Insight 5: three substantive changes have already occurred in the last two years. Decision No. 630-26 (March 2026, second-hand and refurbished devices), the spare-parts import authorization decision (July 3, 2026) and the 2026–2030 strategic framework agreement (February 4, 2026). A change density of this level shows that an annual review rhythm is not enough; a trigger-based mechanism is required. It also shows that the changes arrive from different directions — a decision on second-hand devices, an authorization text for spare parts, a framework agreement — so the monitoring process must be topic-neutral and react to any instrument that touches the portfolio.
4. Practical recommendations
- Set up dual-source monitoring. Watch the Official Gazette for laws, decrees, orders and decisions; watch the AMMPS website for checklist versions, directories and submission channels. Assign an owner to each line.
- Define the five trigger conditions. (1) The authority publishes a new service checklist; (2) implementing decrees or orders of Law 84-12 are amended; (3) the second-hand/refurbished device list changes; (4) fee schedules are adjusted; (5) the authority launches a new submission channel or platform.
- Run quarterly review and trigger-based updating in parallel. Perform a fixed check each quarter; when a trigger fires, complete the review of affected pages or projects within 7 working days.
- Put the checklist version ledger on the project front page. Record the form number, version and application date at project launch, and re-verify before submission. This three-element record costs minutes to maintain and answers, at any later moment, the question of which requirements the project was filed under.
- Retain historical versions and change records. Log every update with its reason and scope of impact, so that the compliance state at any past moment can be reconstructed.
5. Verification checklist
- □ The two monitoring lines — Official Gazette and AMMPS checklists — are set up, each with an owner
- □ The five trigger conditions are written into the procedure with response deadlines
- □ Quarterly review and trigger-based updating run in parallel
- □ The checklist version ledger is created at project launch
- □ The versions of the registration checklist (DE ER DM/01) and the establishment declaration checklist (DE RD-IS-PS/04) are recorded side by side
- □ Historical versions and change records are retained
- □ The three changes of the last two years (630-26, spare-parts authorization, 2026–2030 agreement) have been verified
Regulatory information verified as of October 30, 2026
Post-market support from GRZAN. GRZAN provides post-market compliance support for medical device manufacturers and importers serving the Moroccan market, covering regulatory watch, materiovigilance reporting, recall and withdrawal execution, and inspection and enforcement response. If you want a monitoring mechanism that catches checklist revisions and companion-text changes before they affect your projects, contact info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us